The effect of gastric inhibitory polypeptide on intestinal glucose absorption and intestinal motility in mice |
| |
Authors: | Eiichi Ogawa Masaya Hosokawa Norio Harada Shunsuke Yamane Akihiro Hamasaki Kentaro Toyoda Shimpei Fujimoto Yoshihito Fujita Kazuhito Fukuda Katsushi Tsukiyama Yuichiro Yamada Yutaka Seino Nobuya Inagaki |
| |
Affiliation: | aDepartment of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University, Japan;bFaculty of Human Sciences, Tezukayama Gakuin University, Osaka, Japan;cDepartment of Internal Medicine, Division of Endocrinology, Diabetes and Geriatric Medicine, Akita University School of Medicine, Akita, Japan;dKansai Electric Power Hospital, Osaka, Japan;eCREST of Japan Science and Technology Cooperation (JST), Kyoto, Japan |
| |
Abstract: | Gastric inhibitory polypeptide (GIP) is released from the small intestine upon meal ingestion and increases insulin secretion from pancreatic β cells. Although the GIP receptor is known to be expressed in small intestine, the effects of GIP in small intestine are not fully understood. This study was designed to clarify the effect of GIP on intestinal glucose absorption and intestinal motility. Intestinal glucose absorption in vivo was measured by single-pass perfusion method. Incorporation of [14C]-glucose into everted jejunal rings in vitro was used to evaluate the effect of GIP on sodium-glucose co-transporter (SGLT). Motility of small intestine was measured by intestinal transit after oral administration of a non-absorbed marker. Intraperitoneal administration of GIP inhibited glucose absorption in wild-type mice in a concentration-dependent manner, showing maximum decrease at the dosage of 50 nmol/kg body weight. In glucagon-like-peptide-1 (GLP-1) receptor-deficient mice, GIP inhibited glucose absorption as in wild-type mice. In vitro examination of [14C]-glucose uptake revealed that 100 nM GIP did not change SGLT-dependent glucose uptake in wild-type mice. After intraperitoneal administration of GIP (50 nmol/kg body weight), small intestinal transit was inhibited to 40% in both wild-type and GLP-1 receptor-deficient mice. Furthermore, a somatostatin receptor antagonist, cyclosomatostatin, reduced the inhibitory effect of GIP on both intestinal transit and glucose absorption in wild-type mice. These results demonstrate that exogenous GIP inhibits intestinal glucose absorption by reducing intestinal motility through a somatostatin-mediated pathway rather than through a GLP-1-mediated pathway. |
| |
Keywords: | Abbreviations: GIP, Gastric inhibitory polypeptide GLP-1, glucagon-like-peptide-1 SST, somatostatin SGLT, sodium-glucose co-transporter CSS, cyclosomatostatin |
本文献已被 ScienceDirect 等数据库收录! |
|